FDA approves Takeda's Orzeyful for narcolepsy type 1 in adults

The oral orexin receptor 2 agonist is the first therapy of its kind for narcolepsy with cataplexy and now heads to Drug Enforcement Administration scheduling before a specialty-pharmacy rollout.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.